Clinical and Research Readiness for Spinal Muscular Atrophy: The Time Is Now for Knowledge Translation

Abstract

Disease modifying therapies for spinal muscular atrophy (SMA) are rapidly changing the outlook for many individuals by substantially altering the clinical course, phenotypic expression and functional outcomes. Physical therapists have played critical roles in the effective conduct and execution of clinical trials leading to the approval of these therapies. Given the treatment landscape, educating practicing clinicians to understand best practice is of great importance and a timely call to action to facilitate knowledge translation from SMA researchers to clinicians is necessary. The SMA Clinical Trial Readiness Program engaged clinical and research centers, identified physical therapy knowledge gaps related to evaluation and outcomes assessment, and provided educational resources including the development of a SMA Best Practices Clinical Evaluator Toolkit. Toolkit content synthesizes evidence and covers a breadth of issues relevant to practice, including: background on SMA and the drug pipeline; therapist roles and responsibilities related to research; clinical and research evaluation; and useful materials and resources for additional education, training and professional development. Surveys and telephone interviews were conducted with physical therapists managing individuals with SMA to determine their SMA practice experience and educational needs. Their recommendations, along with synthesized SMA research evidence, provided input into toolkit content development and assisted in identifying gaps important to address. Impact was assessed over time via utilization feedback surveys downloaded by clinicians across various settings. Open-ended feedback supported beneficial use of the toolkit for clinicians and researchers working with individuals with SMA. Next steps should include timely dissemination to bring this resource and others into practice in a systematic, efficacious, and engaging manner. As the treatment landscape for SMA evolves the therapist’s role in multidisciplinary care and research are of great importance and a “call to action” for the development, implementation, evaluation and reporting of informed knowledge, using evidence-based knowledge translation strategies is critical. Impact Partnership among patient advocacy groups, industry collaborators, and key opinion leaders/experts can optimize essential resource development to address the knowledge gap for best practices in physical therapy. This partnership model can be replicated for other diseases providing an efficient way to support clinical trial readiness and target early development of evidence-based content and resources related to both research and best practice clinical evaluation for physical therapist researchers, clinicians, and patients. While identifying knowledge gaps and resource development are initial steps toward change in SMA practice, a rapidly changing rehabilitation outlook warrants a call to action for enhanced efforts aimed at improving rehabilitation evaluation, assessment, and care for this population. It is critical to forge a timely path forward for development, implementation, and sustainability of effective knowledge translation to practice for SMA.

‘High hopes for treatment’: Australian stakeholder perspectives of the clinical translation of advanced neurotherapeutics for rare neurological diseases

“…20 At the clinician–patient interface, as replicated in prior studies, the importance of a well‐curated, accessible, contemporary and ‘single source of truth’ 21 has been recognised to address information needs in healthcare professionals and carers. While toolkits to improve therapeutic readiness, facilitate knowledge dissemination and inform decision‐making have been built on a disease‐specific basis, 22 establishing a consensus approach to management and therapeutic decision‐making by concentrating on the shared pathways between heterogenous diseases may enable a broader view of advanced therapies within the context of RNDs across healthcare systems.…”

Telemedicine Use, Comfort, and Perceived Effectiveness in the Spinal Muscular Atrophy Community

“… 7 , 15 Furthermore, many motor function outcome measures that assess muscle, strength, and reflexes are designed for in-person settings. 6 , 8 , 16 In addition to being important for assessing health status, these measures may be required for coverage of health care services and drug treatments. For these reasons, telemedicine is expected to play a growing role in neuromuscular disease care, but is unlikely to fully supplant in-person care.…”

Validation of a modified version of the Gross Motor Function Measure in PPPR5D related neurodevelopmental disorder

“…Outcome measures will be needed to assess natural history and effects of new treatments in clinical trials for neurogenetic conditions (9). Characterizing motor function with reliable outcome measures will be an important dimension of neurological function to include.…”